EASL Clinical Practice Guidelines: management of cholestatic liver diseases.
about
Vaccination for hepatitis C virus: closing in on an evasive targetPharmacological treatments for primary biliary cirrhosis: a network meta-analysisUrsodeoxycholic acid for primary biliary cirrhosisBezafibrate for primary biliary cirrhosisBisphosphonates for osteoporosis in primary biliary cirrhosisHormone replacement for osteoporosis in women with primary biliary cirrhosisHormone replacement for osteoporosis in women with primary biliary cirrhosisBezafibrate for primary biliary cirrhosisBisphosphonates for osteoporosis in primary biliary cirrhosisPrimary Sclerosing Cholangitis: Therapeutic Options and Surveillance ManagementVitamin D deficiency in patients with liver cirrhosisOsteoporosis in liver disease: pathogenesis and managementNovel bile acid therapeutics for the treatment of chronic liver diseasesBrazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liverSclerosing Cholangitis: Clinicopathologic Features, Imaging Spectrum, and Systemic Approach to Differential DiagnosisAnimal Models for Fibrotic Liver Diseases: What We Have, What We Need, and What Is under DevelopmentPrimary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health PerspectiveLiver Transplantation for Patients with Cholestatic Liver DiseasesHow Should Cancer Surveillance in Primary Sclerosing Cholangitis Be Performed?Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialistsPrimary sclerosing cholangitis: diagnosis and treatmentThe diagnosis of primary biliary cirrhosisPrimary biliary cirrhosis and liver transplantationPrimary biliary cirrhosis: Pathophysiology, clinical presentation and therapyReview article: the management of autoimmune hepatitis beyond consensus guidelinesCholangiocarcinomaDiagnosis and management of the overlap syndromes of autoimmune hepatitisHepatic osteodystrophyAtypical causes of cholestasisPathogenesis of primary sclerosing cholangitis and advances in diagnosis and managementCan serum glypican-3 be a biomarker for effective diagnosis of hepatocellular carcinoma? A meta-analysis of the literatureCombination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysisDiagnosis and Management of Cirrhosis-Related OsteoporosisCirrhosis and autoimmune liver disease: Current understandingRecent advances in the diagnosis and treatment of primary biliary cholangitis.Ursodeoxycholic Acid and S-adenosylmethionine for the Treatment of Intrahepatic Cholestasis of Pregnancy: A Meta-analysisJaundice associated pruritis: a review of pathophysiology and treatmentCystic fibrosis related liver disease--another black box in hepatology.Autoimmune liver diseases in the Asia-Pacific region: Proceedings of APASL symposium on AIH and PBC 2016.Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.
P2860
Q22305922-F96459B7-5F89-44B5-94D3-2922924EFF47Q24186852-BB285082-9A92-4C04-9285-E6FEFDA145F6Q24202184-CCEA955A-9D6C-4897-B7D9-F9232D252A19Q24203847-C351634F-11A5-4D52-8211-CC3AC8402ADDQ24234283-99102BDB-CDC4-4F98-85A9-F0BC48C67629Q24234575-C264FF9A-E00C-45D2-8E08-1B8508933E19Q24234784-B43B51CE-C55E-4230-824C-A0E82B8EF30EQ24234884-A0740F10-AA74-46A0-A3B6-7FA4E7F20FD0Q24234967-C4803926-4671-41FB-90EF-D20F9E5FB37FQ26744040-2B4C2BC6-6697-4862-B5D3-F64B402FCC18Q26745766-541EFC26-1562-440C-B458-C4B0C2CE5D22Q26746935-001172EC-F6B7-48EF-9829-1A45388713E0Q26748613-D8F7966D-75F6-4C35-87C7-EA0C604EC9EBQ26766699-03768499-7D9F-4CBC-AAB2-9D0E78D3C12FQ26770016-6EE2ECE5-2131-493D-8189-702F89A43EB5Q26781761-3250AB4B-FA45-4067-A101-E5E2D8758FDFQ26781780-F4640D7D-5C51-4FBB-A5F2-33FBFD3243BEQ26782863-266224B6-009F-4A8D-A992-2DE063F453E2Q26782878-5A302D63-2150-4DF1-B7D2-911D7BDA2116Q26796355-39F5842C-F310-42F9-A5AD-BFD2850E40AAQ26829216-B84AAA7B-FA6A-462F-8558-28C9BE4BEC97Q26829493-6BDA0B3F-3B69-4171-B69E-0483070D000CQ26853145-D364678F-6B21-41DE-B194-8FF810211DA2Q26853649-127ADFD5-1BEC-4AAB-868A-3226A5D78098Q26864272-6114272A-5A6F-4821-8361-2DEC67E24C10Q27001694-ADDD28B5-E5A2-44C9-9CAF-1BAEB80D3C59Q27003179-A0A94288-AAA1-4386-ADCF-FAFE5E50F46EQ27004571-32E51775-7C46-4EB6-9176-3177372CDA40Q27013650-D8B2DB59-8E6F-4650-9234-1CEAAE09D3DEQ27015831-D686D548-34F9-4139-B7F1-68DCDE135ABCQ27023427-349E7CB0-E584-4209-9DBC-81DFA37F78ACQ27023986-D766F05F-60D9-4439-B9E1-3CFA6B47DE21Q28069053-78E14D85-0E24-4DDA-935A-CBC23C33B841Q28070154-B60FB386-FC0E-47C7-9AB3-D8C9A693AD4DQ28076353-1F83B1E2-A0C1-4311-B9BE-6330EE2D9C25Q28078484-166521E2-CB32-477F-8293-474FEC7FA15EQ28084371-F7D9C7AA-4BF0-4A34-BDCC-3707E1F3B3D2Q28655881-58779280-7191-4E4C-AD21-6F94B91FFA9EQ30244056-2A9621D7-298A-4384-815E-0F418A865E39Q30435394-A8350649-FF3E-458B-AC1F-9618704AE548
P2860
EASL Clinical Practice Guidelines: management of cholestatic liver diseases.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
EASL Clinical Practice Guidelines: management of cholestatic liver diseases.
@en
EASL Clinical Practice Guidelines: management of cholestatic liver diseases.
@nl
type
label
EASL Clinical Practice Guidelines: management of cholestatic liver diseases.
@en
EASL Clinical Practice Guidelines: management of cholestatic liver diseases.
@nl
prefLabel
EASL Clinical Practice Guidelines: management of cholestatic liver diseases.
@en
EASL Clinical Practice Guidelines: management of cholestatic liver diseases.
@nl
P1476
EASL Clinical Practice Guidelines: management of cholestatic liver diseases.
@en
P2093
European Association for the Study of the Liver
P304
P356
10.1016/J.JHEP.2009.04.009
P577
2009-06-06T00:00:00Z